These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 21844838)

  • 1. Bethanechol for buprenorphine-related urinary hesitancy: a case series.
    Varma A; Smigiel J; Eck N; Brooks S
    J Addict Med; 2011 Sep; 5(3):227-8. PubMed ID: 21844838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence.
    Bell J; Byron G; Gibson A; Morris A
    Drug Alcohol Rev; 2004 Sep; 23(3):311-7. PubMed ID: 15370011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early experience with Suboxone maintenance therapy in Hungary.
    Demetrovics Z; Farkas J; Csorba J; Németh A; Mervó B; Szemelyácz J; Fleischmann E; Kassai-Farkas A; Petke Z; Oroján T; Rózsa S; Rigó P; Funk S; Kapitány M; Kollár A; Rácz J
    Neuropsychopharmacol Hung; 2009 Dec; 11(4):249-57. PubMed ID: 20150662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of heroin overdose reversed by sublingually administered buprenorphine/naloxone (Suboxone).
    Welsh C; Sherman SG; Tobin KE
    Addiction; 2008 Jul; 103(7):1226-8. PubMed ID: 18554353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.
    Alho H; Sinclair D; Vuori E; Holopainen A
    Drug Alcohol Depend; 2007 Apr; 88(1):75-8. PubMed ID: 17055191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preference for buprenorphine/naloxone and buprenorphine among patients receiving buprenorphine maintenance therapy in France: a prospective, multicenter study.
    Daulouède JP; Caer Y; Galland P; Villeger P; Brunelle E; Bachellier J; Piquet JM; Harbonnier J; Leglise Y; Courty P
    J Subst Abuse Treat; 2010 Jan; 38(1):83-9. PubMed ID: 19800758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post marketing surveillance of sublingual buprenorphine naloxone combination tablets.
    Ray R; Vaswani M; Deb KS; Sethi H; Chopra A; Kishore N; Goyal R
    Indian J Physiol Pharmacol; 2012; 56(4):359-66. PubMed ID: 23781656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
    Mammen K; Bell J
    Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine and naloxone interactions in methadone maintenance patients.
    Mendelson J; Jones RT; Welm S; Brown J; Batki SL
    Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term buprenorphine maintenance: treatment outcome.
    Galanter M; Dermatis H; Resnick R; Maslansky R; Neumann E
    J Addict Dis; 2003; 22(3):39-49. PubMed ID: 14621343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Less pain, more gain: buprenorphine-naloxone and patient retention in treatment.
    Renzelli CM; Capretto NA
    J Addict Dis; 2006; 25(3):97-104. PubMed ID: 16956874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of continuous monitoring of spontaneous respiration in the postoperative phase. 2. Cutaneous oxygen and carbon dioxide partial pressures following i.v. bolus application of fentanyl, buprenorphine, naloxone and amiphenazole in healthy adult subjects].
    Lehmann KA; Huttarsch H; Schroeder B; Zech D
    Anaesthesist; 1992 Apr; 41(4):192-8. PubMed ID: 1350432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diverse clinical uses of opioid receptor drugs.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2010 May; 48(5):11-4. PubMed ID: 20415289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
    Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D;
    N Engl J Med; 2003 Sep; 349(10):949-58. PubMed ID: 12954743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
    Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
    Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
    Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin syndrome triggered by a single dose of suboxone.
    Isenberg D; Wong SC; Curtis JA
    Am J Emerg Med; 2008 Sep; 26(7):840.e3-5. PubMed ID: 18774063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine and naloxone interactions in opiate-dependent volunteers.
    Mendelson J; Jones RT; Fernandez I; Welm S; Melby AK; Baggott MJ
    Clin Pharmacol Ther; 1996 Jul; 60(1):105-14. PubMed ID: 8689806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine use by the smoking route in gaols in NSW.
    Winstock AR
    Drug Alcohol Rev; 2008 Jul; 27(4):449-50. PubMed ID: 18584400
    [No Abstract]   [Full Text] [Related]  

  • 20. Suboxone (buprenorphine/naloxone) toxicity in pediatric patients: a case report.
    Schwarz KA; Cantrell FL; Vohra RB; Clark RF
    Pediatr Emerg Care; 2007 Sep; 23(9):651-2. PubMed ID: 17876257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.